After snapping up Parexel with Goldman Sachs, EQT doubles down on healthcare with Life Sciences Partners buyout

The ink in EQT’s checkbook is still not quite dry from the $8.5 billion it and Goldman Sachs spent on CRO Parexel back in March, but it will need a fresh page as it snaps up a major European healthcare venture capital firm.

There’s around $520 million (450 million euros) coming upfront from investment firm EQT to buy Life Sciences Partners (LSP), made up of 25% cash and 75% EQT AB publicly traded shares, with 25 million euros also up for grabs “if certain short-term fundraising targets are met.”